Эльбона®

General characteristics. Structure:

Solution A: the ampoule of 3 ml contains in 2 ml of solution: active agent - a glycosamine of sodium sulfate of chloride of 502,5 mg (corresponds a glycosamine of sulfate of 400 mg and sodium of chloride of 102,5 mg).

Excipients: a trometamola to рН 2,0 3,0, lidocaine of a hydrochloride of 10,0 mg, water for injections - to 2,0 ml.

Solution B: 1 ml of solution contains: diethanol amide — 24,0 mg, waters for injections - to 1,0 ml.

Description: solution A - colourless or light yellow transparent liquid, solution B - colourless transparent liquid. Solution A plus solution B - light yellow transparent liquid.

Pharmacological properties:

Glycosamine sulfate possesses antiinflammatory action and the anesthetizing action, fills endogenous shortage of a glycosamine, stimulates synthesis of proteoglycans and hyaluronic acid of synovial fluid; promotes fixing of sulfur in the course of synthesis of chondroitinsulphuric acid, slows down development of degenerative processes in joints, recovers their function. The glycosamine promotes prevention of processes of destruction of a cartilage, stimulates recovery of cartilaginous tissue. Improves mobility of joints, reduces the need for non-steroidal anti-inflammatory drugs (NPVP).

Indications to use:

Primary and secondary osteoarthritis, spondylarthrosis.

Route of administration and doses:

Intramusculary! Drug is not intended for intravenous administration. Before use to mix solution B (solvent) with solution A (solution drug) in one syringe. The prepared solution of drug is entered intramusculary on 3 ml (solutions A + B) by 3 times a week for 4-6 weeks.

Side effects:

Portability of drug good. Are in some cases possible: a meteorism, diarrhea, a lock, allergic reactions - urticaria, an itch.

Because of the content in drug of lidocaine are possible: nausea, vomiting, drowsiness, diplopia, headache, dizziness, numbness of language and mucous membrane of a mouth, tremor, euphoria, disorientation, disturbance of cordial conductivity, anaphylactic reactions.

Interaction with other medicines:

Let's combine with non-steroidal anti-inflammatory drugs, paracetamol and glucocorticosteroids.

Cimetidinum and propranolol reduce hepatic clearance of lidocaine (decrease in metabolism owing to inhibition of a microsomal oxidation and decrease in a hepatic blood-groove) and increase risk of development of toxic effects.

At appointment with Ajmalinum, Phenytoinum, verapamil, quinidine, Amiodaronum strengthening of a negative inotropic effect is possible. Joint appointment with beta adrenoblockers increases risk of development of bradycardia. Cardiac glycosides weaken cardiotonic effect, kurarenodobny medicines strengthen a muscular relaxation. Procaineamide increases risk of development of excitement of the central nervous system, hallucinations.

At co-administration of somnolent and sedative medicines strengthening of their oppressing action on the central nervous system is possible.

At intravenous administration of hexobarbital or sodium thiopental against the background of effect of lidocaine respiratory depression is possible.

Exponentiates effects of MAO inhibitors.

At simultaneous use with polymyxin B strengthening of the oppressing influence on neuromuscular transmission therefore in that case it is necessary to monitor function of breath of the patient is possible. Reduction of efficiency of antidiabetic drugs, doxorubicine, a tenipozid, etopozid is possible.

Contraindications:

Individual hypersensitivity to a glycosamine, lidocaine to a hydrochloride and other components of drug, a fenilketonuriya. Owing to availability of lidocaine as a part of a product, it is contraindicated to patients with disturbances of cordial conductivity and an acute heart failure, epileptiform spasms in the anamnesis, heavy disturbances of functions of a liver and kidneys; during pregnancy and a lactation, and also at children's age up to 12 years.

 

With care patients should use drug with chronic heart failure, arterial hypotonia, bronchial asthma, a diabetes mellitus. At intolerance of seafood (shrimps, mollusks) the probability of development of allergic reactions to drug increases.

Overdose:

Cases of overdose are noted.

Storage conditions:

In the dry, protected from light place, at a temperature not above 25 °C. To store in the places unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Solution for intramuscular introduction of 200 mg/ml on 2 ml in ampoules And light-protective glass. Solvent on 1 ml in ampoules of B of neutral glass. 6 ampoules And with drug in a blister strip packaging from a film of PVC and 6 ampoules of B with solvent in a blister strip packaging from P BX film, or 6 ampoules And with drug and 6 ampoules of B with solvent place in a blister strip packaging and films of PVC which will prevent in a pack from a cardboard together with the application instruction.